Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

ClinicalTrials.gov ID: NCT00323739

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00323739. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent.

Study identification

NCT ID
NCT00323739
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
80 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2006 (Type not available)
Primary completion
Nov 2008 (Actual)
Completion
Mar 2011 (Actual)
Last update posted
Jul 26, 2013

2006 – 2011

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
Florida Cancer Specialists Fort Myers Florida 33901 —
Gainsville Hematology Oncology Associates Gainesville Florida 32605 —
Integrated Community Oncology Network Jacksonville Florida 32256 —
Florida Hospital Cancer Institute Orlando Florida 32804 —
Wellstar Cancer Research Marietta Georgia 30060 —
Consultants in Blood Disorders and Cancer Louisville Kentucky 40207 —
Baton Rouge General Medical Center Baton Rouge Louisiana 70806 —
Grand Rapids Clinical Oncology Program Grand Rapids Michigan 49503 —
Methodist Cancer Center Omaha Nebraska 68114 —
Oncology Hematology Care Cincinnati Ohio 45242 —
Chattanooga Oncology Hematology Associates Chattanooga Tennessee 37404 —
Tennessee Oncology, PLLC Nashville Tennessee 37023 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00323739, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 26, 2013 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.